Naesens M - Search Results

1

Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.

Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Naesens M, et al. Transplantation. 2006 Oct 27;82(8):1074-84. doi: 10.1097/01.tp.0000235533.29300.e7. Transplantation. 2006. PMID: 17060857

2

Bartter's and Gitelman's syndromes: from gene to clinic.

Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Naesens M, et al. Nephron Physiol. 2004;96(3):p65-78. doi: 10.1159/000076752. Nephron Physiol. 2004. PMID: 15056980 Review.

3

Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase.

Kuypers DR, Verleden G, Naesens M, Vanrenterghem Y. Kuypers DR, et al. Among authors: naesens m. Clin Pharmacol Ther. 2005 Jul;78(1):81-8. doi: 10.1016/j.clpt.2005.03.004. Clin Pharmacol Ther. 2005. PMID: 16003296

4

The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.

Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. Kuypers DR, et al. Among authors: naesens m. Clin Pharmacol Ther. 2005 Oct;78(4):351-61. doi: 10.1016/j.clpt.2005.06.007. Clin Pharmacol Ther. 2005. PMID: 16198654 Clinical Trial.

5

Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients.

Naesens M, Verbeke K, Vanrenterghem Y, Kuypers D. Naesens M, et al. Br J Clin Pharmacol. 2007 May;63(5):541-7. doi: 10.1111/j.1365-2125.2006.02813.x. Epub 2006 Nov 10. Br J Clin Pharmacol. 2007. PMID: 17094777 Free PMC article.

6

Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.

Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y. Naesens M, et al. Clin Pharmacol Ther. 2006 Nov;80(5):509-21. doi: 10.1016/j.clpt.2006.08.002. Clin Pharmacol Ther. 2006. PMID: 17112807 Clinical Trial.

7

Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients.

Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y. Evenepoel P, et al. Among authors: naesens m. Am J Transplant. 2007 May;7(5):1193-200. doi: 10.1111/j.1600-6143.2007.01753.x. Epub 2007 Mar 12. Am J Transplant. 2007. PMID: 17359508 Free article. Clinical Trial.

8

CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.

Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. Kuypers DR, et al. Among authors: naesens m. Clin Pharmacol Ther. 2007 Dec;82(6):711-25. doi: 10.1038/sj.clpt.6100216. Epub 2007 May 9. Clin Pharmacol Ther. 2007. PMID: 17495880

9

Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year.

Lerut E, Naesens M, Kuypers DR, Vanrenterghem Y, Van Damme B. Lerut E, et al. Among authors: naesens m. Transplantation. 2007 Jun 15;83(11):1416-22. doi: 10.1097/01.tp.0000266676.10550.70. Transplantation. 2007. PMID: 17565313

10

Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation.

Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DR. Naesens M, et al. Am J Transplant. 2007 Sep;7(9):2114-23. doi: 10.1111/j.1600-6143.2007.01892.x. Epub 2007 Jul 3. Am J Transplant. 2007. PMID: 17608835 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

293 results

Search Page

Filters